Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 5 | 4 |
List of Tables | 7 | 1 |
List of Figures | 8 | 1 |
Introduction | 9 | 1 |
South Korea Pharmaceutical Market Outlook 2013 Overview | 10 | 19 |
Global Pharmaceutical Industry Landscape | 10 | 1 |
Macroscopic View of the South Korea Pharmaceutical Market | 10 | 2 |
Trade Balance | 12 | 1 |
Exports | 13 | 3 |
Imports | 16 | 2 |
Demographic Analysis | 18 | 1 |
Population Size, Growth, and Structure | 18 | 1 |
Crude Death Rate | 19 | 1 |
Causes of Death | 20 | 2 |
Crude Birth Rate | 22 | 1 |
Infant Mortality Rate | 23 | 1 |
Life Expectancy at Birth | 24 | 1 |
Comparison of Healthcare Indicators | 25 | 1 |
Driver and Barriers of South Korean Pharmaceutical Industry | 26 | 1 |
Drivers | 26 | 1 |
Rapidly Aging Population | 26 | 1 |
Supportive Government Policies and Investments | 26 | 1 |
Conducive Environment for Clinical Trials | 27 | 1 |
Insurance Coverage of the Entire Population | 27 | 1 |
Barriers | 28 | 1 |
Government s Limitations on Drug Reimbursements | 28 | 1 |
Revised Pricing Measures | 28 | 1 |
FTAs Effect on Domestic Companies | 28 | 1 |
South Korea Pharmaceutical Market Outlook 2013 Industry Characteristics | 29 | 12 |
Regulatory Agencies | 29 | 1 |
Korea Food and Drug Administration | 29 | 1 |
National Institute of Food and Drug Safety Evaluation | 30 | 1 |
Drug Pricing Policy | 31 | 1 |
Healthcare Expenditure in South Korea | 32 | 5 |
Healthcare Infrastructure | 37 | 1 |
Insurance and Reimbursement | 38 | 1 |
National Health Insurance | 38 | 1 |
Long-term Care Insurance | 39 | 1 |
Medical Aid | 40 | 1 |
South Korea Pharmaceutical Market Outlook 2013 Market Analysis | 41 | 7 |
Over-the-Counter drugs | 41 | 1 |
Prescription Drugs | 42 | 1 |
Patented Drugs | 43 | 1 |
Generics | 44 | 1 |
Biotechnology | 45 | 3 |
South Korea Pharmaceutical Market Outlook 2013 Key Trends | 48 | 7 |
Rapid Consolidations in the Domestic Market | 48 | 1 |
M&A deals | 48 | 2 |
Partnership Deals | 50 | 1 |
Licensing Deals | 51 | 1 |
Understanding Local Markets to Build R&D | 52 | 1 |
Free Trade Agreements | 53 | 1 |
Intellectual Property Rights Protection | 54 | 1 |
Transparency in Healthcare Regulatory and Reimbursement Process | 54 | 1 |
Unethical Business Practices | 54 | 1 |
South Korea Pharmaceutical Market Outlook 2013 Competitive Landscape | 55 | 6 |
Key Foreign Companies | 55 | 1 |
GlaxoSmithKline | 55 | 1 |
Sanofi | 55 | 1 |
Pfizer | 56 | 1 |
Key Domestic Companies | 57 | 1 |
Dong-A | 57 | 1 |
Green Cross | 58 | 1 |
Hanmi | 59 | 1 |
JW Holdings Corporation (Choongwae Holdings Co., Ltd.) | 60 | 1 |
Yuhan Corporation | 60 | 1 |
South Korea Pharmaceutical Market Outlook 2013 The Way Forward | 61 | 2 |
Outlook | 61 | 1 |
Opportunities Ahead | 61 | 1 |
Biosimilars | 61 | 1 |
Stem Cell Research | 61 | 2 |
South Korea Pharmaceutical Market Outlook 2013 Appendix | 63 | 5 |
Market Definitions | 63 | 1 |
Abbreviations | 63 | 1 |
Bibliography | 64 | 2 |
Research Methodology | 66 | 2 |
Coverage | 66 | 1 |
Secondary Research | 66 | 1 |
Primary Research | 66 | 1 |
Expert Panel Validation | 67 | 1 |
Contact Us | 67 | 1 |
Disclaimer | 67 | 1 |